Loading clinical trials...
Loading clinical trials...
Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon
Conditions
Interventions
recombinant interferon alfa
amifostine trihydrate
+6 more
Locations
4
United States
Cook County Hospital
Chicago, Illinois, United States
Rush Cancer Institute
Chicago, Illinois, United States
Angelo P. Creticos, M.D. Cancer Center
Chicago, Illinois, United States
Rush-Riverside Cancer Center
Kankakee, Illinois, United States
Start Date
April 1, 1998
Primary Completion Date
April 1, 1999
Completion Date
April 1, 1999
Last Updated
October 14, 2021
NCT05564390
NCT06846671
NCT07320235
NCT06514534
NCT05475925
NCT07218341
Lead Sponsor
Rush University Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions